未经证实的细胞干预措施带来的财务风险：从日本的医疗费用扣除中估算退款。
Financial risks posed by unproven cell interventions: Estimation of refunds from medical expense deductions in Japan.
机构信息
Shizuoka Graduate University of Public Health, Aoi-ku, Shizuoka 420-0881, Japan.
Division of Scientific Information and Public Policy, Center for Infectious Disease Education and Research, Osaka University, Suita, Osaka 565-0871, Japan; Research Center on Ethical, Legal and Social Issues, Osaka University, Suita, Osaka 565-0871, Japan.
出版信息
Stem Cell Reports. 2022 May 10;17(5):1016-1018. doi: 10.1016/j.stemcr.2022.03.015. Epub 2022 Apr 21.
Abstract
Master et al. (2021) declared that the unproven stem cell intervention (SCI) industry is a global health problem. We fully agree with this opinion but would like to point out that there are financial risks. In this letter, we estimate the total refund amount paid by the government for cell-based interventions offered under private practice in Japan.
摘要
马斯特等人（2021 年）宣称未经证实的干细胞干预（SCI）产业是一个全球性的健康问题。我们完全同意这一观点，但想指出的是，这其中存在财务风险。在这封信中，我们估计了日本私人执业中提供的基于细胞的干预措施，政府为此支付的退款总额。
相似文献
1
Financial risks posed by unproven cell interventions: Estimation of refunds from medical expense deductions in Japan.未经证实的细胞干预措施带来的财务风险：从日本的医疗费用扣除中估算退款。
Stem Cell Reports. 2022 May 10;17(5):1016-1018. doi: 10.1016/j.stemcr.2022.03.015. Epub 2022 Apr 21.
2
Unproven stem cell interventions: A global public health problem requiring global deliberation.未经证实的干细胞干预措施：一个需要全球商讨的全球公共卫生问题。
Stem Cell Reports. 2021 Jun 8;16(6):1435-1445. doi: 10.1016/j.stemcr.2021.05.004.
3
Academic physician specialists' views toward the unproven stem cell intervention industry: areas of common ground and divergence.学术医师专家对未经证实的干细胞干预产业的看法：共识和分歧领域。
Cytotherapy. 2021 Apr;23(4):348-356. doi: 10.1016/j.jcyt.2020.12.011. Epub 2021 Feb 6.
4
[Impact Reimbursement Act on the pharmaceutical market in Poland].[《影响波兰药品市场的报销法案》]
Pol Merkur Lekarski. 2014 Apr;36(214):270-3.
5
Designing persuasive health education for patients seeking unproven stem cell interventions.为寻求未经证实的干细胞干预的患者设计有说服力的健康教育。
Stem Cell Reports. 2023 Aug 8;18(8):1549-1554. doi: 10.1016/j.stemcr.2023.06.004.
6
Unproven stem cell-based interventions & physicians' professional obligations; a qualitative study with medical regulatory authorities in Canada.未经证实的基于干细胞的干预措施与医生的职业义务；对加拿大医学监管机构的定性研究
BMC Med Ethics. 2014 Oct 14;15:75. doi: 10.1186/1472-6939-15-75.
7
Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventions.民事诉讼能否遏制未经证实的干细胞干预措施面向消费者的直接营销浪潮？
NPJ Regen Med. 2018 Feb 19;3:5. doi: 10.1038/s41536-018-0043-6. eCollection 2018.
8
Do benefits in kind or refunds affect health service utilization and health outcomes? A natural experiment from Japan.实物福利或退款会影响医疗服务利用和健康结果吗？一项来自日本的自然实验。
Health Policy. 2017 May;121(5):534-542. doi: 10.1016/j.healthpol.2017.02.016. Epub 2017 Mar 12.
9
Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions.简明综述：接受未经证实的干细胞干预治疗的患者报告不良事件的综合分析。
Stem Cells Transl Med. 2018 Sep;7(9):676-685. doi: 10.1002/sctm.17-0282. Epub 2018 Jul 31.
10
The involvement of Canadian physicians in promoting and providing unproven and unapproved stem cell interventions.加拿大医生参与推广和提供未经证实且未获批准的干细胞干预措施。
BMC Med Ethics. 2018 May 2;19(1):32. doi: 10.1186/s12910-018-0273-6.
本文引用的文献
1
The American stem cell sell in 2021: U.S. businesses selling unlicensed and unproven stem cell interventions.2021 年美国的干细胞买卖：美国企业销售未经许可和未经证实的干细胞干预措施。
Cell Stem Cell. 2021 Nov 4;28(11):1891-1895. doi: 10.1016/j.stem.2021.10.008.
2
Unproven stem cell interventions: A global public health problem requiring global deliberation.未经证实的干细胞干预措施：一个需要全球商讨的全球公共卫生问题。
Stem Cell Reports. 2021 Jun 8;16(6):1435-1445. doi: 10.1016/j.stemcr.2021.05.004.
3
Reflection on the enactment and impact of safety laws for regenerative medicine in Japan.关于日本再生医学安全法规的制定和影响的思考。
Stem Cell Reports. 2021 Jun 8;16(6):1425-1434. doi: 10.1016/j.stemcr.2021.04.017. Epub 2021 May 20.
4
The potent effects of Japan's stem-cell policies.日本干细胞政策的强大影响。
Nature. 2019 Sep;573(7775):482-485. doi: 10.1038/d41586-019-02847-3.
5
Direct-to-consumer marketing of stem cell interventions by Canadian businesses.加拿大企业面向消费者的干细胞干预疗法营销。
Regen Med. 2018 Sep;13(6):643-658. doi: 10.2217/rme-2018-0033. Epub 2018 Sep 26.
6
Global Distribution of Businesses Marketing Stem Cell-Based Interventions.全球营销基于干细胞的干预措施的企业分布。
Cell Stem Cell. 2016 Aug 4;19(2):158-162. doi: 10.1016/j.stem.2016.07.015.
7
Evaluating the Quality of Website Information of Private-Practice Clinics Offering Cell Therapies in Japan.评估日本提供细胞疗法的私人诊所网站信息的质量。
Interact J Med Res. 2016 May 24;5(2):e15. doi: 10.2196/ijmr.5479.
8
Recent Court Ruling in Japan Exemplifies Another Layer of Regulation for Regenerative Therapy.日本近期的法庭裁决体现了再生疗法监管的另一层面。
Cell Stem Cell. 2015 Nov 5;17(5):507-8. doi: 10.1016/j.stem.2015.10.008.
9
The current status of clinics providing private practice cell therapy in Japan.日本提供私人执业细胞治疗的诊所的现状。
Regen Med. 2016 Jan;11(1):23-32. doi: 10.2217/rme.15.64. Epub 2015 Sep 17.
10
New Japanese initiatives on stem cell therapies.日本在干细胞疗法方面的新举措。
Cell Stem Cell. 2015 Apr 2;16(4):350-2. doi: 10.1016/j.stem.2015.03.012.
Zotero 插件